Latigo Biotherapeutics (LTGO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $14.76, +5.43% vs the prior close of $14.00.
- Volume 242.90K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LTGO jumps 5.4% to $14.76. Closed at $14.76, +5.43% vs the prior close of $14.00. Day range $13.50–$14.90, opened at $14.09.
LTGO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — LTGO jumps 5.4% to $14.76
- Closed at $14.76, +5.43% vs the prior close of $14.00. Day range $13.50–$14.90, opened at $14.09.
- Volume was 242.90K shares, 0.6x its 50-day average of 377.09K.
- 52-week range $13.50–$25.93; today's close sits at 10% of that range, 43.1% below the 52-week high.
Oct 14, 2026 — LTGO slides 10.9% to $14.00, a 1-month low
- Closed at $14.00, -10.88% vs the prior close of $15.71. Day range $13.85–$15.74, opened at $15.74.
- Volume was 220.60K shares, 0.6x its 50-day average of 380.42K — lighter than usual.
- 52-week range $13.85–$25.93; today's close sits at 1% of that range, 46.0% below the 52-week high.
Oct 13, 2026 — LTGO dips 1.9% to $15.71
- Closed at $15.71, -1.94% vs the prior close of $16.02. Day range $15.56–$16.51, opened at $16.12.
- Volume was 346.80K shares, 0.9x its 50-day average of 381.15K.
- 52-week range $14.60–$25.93; today's close sits at 10% of that range, 39.4% below the 52-week high.
Oct 12, 2026 — LTGO ends flat (+0.1%) to $16.02
- Closed at $16.02, +0.13% vs the prior close of $16.00. Day range $15.80–$16.56, opened at $16.00.
- Volume was 133.00K shares, 0.3x its 50-day average of 386.66K — lighter than usual.
- 52-week range $14.60–$25.93; today's close sits at 13% of that range, 38.2% below the 52-week high.
Oct 9, 2026 — LTGO jumps 8.2% to $16.00
- Closed at $16.00, +8.18% vs the prior close of $14.79. Day range $14.61–$16.08, opened at $14.84.
- Volume was 184.20K shares, 0.5x its 50-day average of 391.26K — lighter than usual.
- 52-week range $14.60–$25.93; today's close sits at 12% of that range, 38.3% below the 52-week high.
Oct 8, 2026 — LTGO slides 4.7% to $14.79, a 1-month low, 3 down days in a row
- Closed at $14.79, -4.70% vs the prior close of $15.52. Day range $14.60–$15.52, opened at $15.52.
- Volume was 265.10K shares, 0.7x its 50-day average of 394.20K.
- 52-week range $14.60–$25.93; today's close sits at 2% of that range, 43.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — LTGO slides 4.6% to $15.52, a 1-month low
- Closed at $15.52, -4.55% vs the prior close of $16.26. Day range $15.27–$16.35, opened at $16.22.
- Volume was 241.50K shares, 0.6x its 50-day average of 397.83K.
- 52-week range $15.27–$25.93; today's close sits at 2% of that range, 40.1% below the 52-week high.
Oct 6, 2026 — LTGO dips 2.2% to $16.26
- Closed at $16.26, -2.22% vs the prior close of $16.63. Day range $16.06–$16.89, opened at $16.77.
- Volume was 544.50K shares, 1.4x its 50-day average of 394.26K.
- 52-week range $15.67–$25.93; today's close sits at 6% of that range, 37.3% below the 52-week high.
Oct 5, 2026 — LTGO jumps 4.6% to $16.63
- Closed at $16.63, +4.59% vs the prior close of $15.90. Day range $15.87–$17.07, opened at $16.06.
- Volume was 590.00K shares, 1.5x its 50-day average of 389.36K.
- 52-week range $15.67–$25.93; today's close sits at 9% of that range, 35.9% below the 52-week high.
Oct 2, 2026 — LTGO slides 4.7% to $15.90, a 1-month low, 3 down days in a row
- Closed at $15.90, -4.73% vs the prior close of $16.69. Day range $15.67–$16.90, opened at $16.80.
- Volume was 276.60K shares, 0.7x its 50-day average of 392.25K.
- 52-week range $15.67–$25.93; today's close sits at 2% of that range, 38.7% below the 52-week high.
- That makes 3 straight losses.
LTGO latest news & SEC filings
Every SEC filing by or about LTGO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$25.80M (prior year -$25.84M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$27.59 (prior year -$36.52) (loss narrowed vs Jun 30, 2025)
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 18, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Foresite Capital Fund Vi Lp bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
- Foresite Capital Opportunity Fund V, L.P. bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
- Foresite Capital Fund V, L.P. bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
- Foresite Capital Management Vi Llc bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
- Foresite Capital Management V, Llc bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
- Foresite Capital Opportunity Management V, Llc bought 140,000 shares at $18.00 (≈$2.52M) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form 424B4 — Final prospectus with offering price
Final prospectus with offering price
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade LTGO
- Last results release: Sep 3, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 4.64% (largest 11.1%). That is a volatile stock.
- Liquidity: about 418.97K shares (≈$6.18M) trade per day on average.
- 52-week position: $14.76 vs a range of $13.50–$25.93 (10% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 7 open-market buys, 0 sales; latest: James B. Tananbaum bought 140,000 shares on Aug 10, 2026.
- Latest filings: 10-Q Sep 3, 2026; 8-K Sep 3, 2026; 8-K Aug 10, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LTGO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 14.09 | 14.90 | 13.50 | 14.76 | 242.90K |
| Oct 14, 2026 | 15.74 | 15.74 | 13.85 | 14.00 | 220.60K |
| Oct 13, 2026 | 16.12 | 16.51 | 15.56 | 15.71 | 346.80K |
| Oct 12, 2026 | 16.00 | 16.56 | 15.80 | 16.02 | 133.00K |
| Oct 9, 2026 | 14.84 | 16.08 | 14.61 | 16.00 | 184.20K |
| Oct 8, 2026 | 15.52 | 15.52 | 14.60 | 14.79 | 265.10K |
| Oct 7, 2026 | 16.22 | 16.35 | 15.27 | 15.52 | 241.50K |
| Oct 6, 2026 | 16.77 | 16.89 | 16.06 | 16.26 | 544.50K |
| Oct 5, 2026 | 16.06 | 17.07 | 15.87 | 16.63 | 590.00K |
| Oct 2, 2026 | 16.80 | 16.90 | 15.67 | 15.90 | 276.60K |
| Oct 1, 2026 | 16.70 | 17.55 | 16.48 | 16.69 | 436.70K |
| Sep 30, 2026 | 18.04 | 18.32 | 16.25 | 16.70 | 532.60K |
| Sep 29, 2026 | 17.33 | 18.50 | 17.30 | 18.10 | 955.20K |
| Sep 28, 2026 | 17.15 | 17.84 | 16.19 | 17.48 | 260.30K |
| Sep 25, 2026 | 17.81 | 18.26 | 17.00 | 17.15 | 275.70K |
| Sep 24, 2026 | 19.73 | 20.54 | 17.67 | 17.76 | 340.70K |
| Sep 23, 2026 | 20.77 | 20.79 | 19.71 | 19.97 | 214.60K |
| Sep 22, 2026 | 21.11 | 21.33 | 20.01 | 20.82 | 418.80K |
| Sep 21, 2026 | 22.80 | 23.11 | 21.00 | 21.11 | 411.40K |
| Sep 18, 2026 | 24.18 | 24.80 | 22.21 | 22.55 | 1.49M |
About Latigo Biotherapeutics
Latigo Biotherapeutics (LTGO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in THOUSAND OAKS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2056611.
LTGO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sara Bonstein | Director | Aug 6, 2026 |
| Nima Farzan | President and CEO | Aug 6, 2026 |
| Kevin Raidy | Director | Aug 6, 2026 |
| Beth C Seidenberg | Director | Aug 10, 2026 |
| Todd N Smith | Director | Aug 10, 2026 |
| James B. Tananbaum | Director | Aug 10, 2026 |
| Timothy P Walbert | Director | Aug 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Nima Farzan | President and CEO | Aug 6, 2026 |
| Neha Krishnamohan | CFO and Chief Business Officer | Aug 6, 2026 |
| Neil Singla | Chief Medical Officer | Aug 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 10, 2026 | James B. Tananbaum | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Fund Vi Lp Foresite | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Opportunity Fund V, L.P. Foresite | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Fund V, L.P. Foresite | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Management Vi Llc Foresite | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Management V, Llc Foresite | Buy | 140,000 | $18.00 |
| Aug 10, 2026 | Capital Opportunity Management V, Llc Foresite | Buy | 140,000 | $18.00 |
LTGO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $64.76M, total liabilities $52.26M, cash $55.00M (as of Jun 30, 2026).
LTGO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 3, 2026 | 8-K Item 2.02 (results) | $22.48 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on LTGO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.